tiprankstipranks
Advertisement
Advertisement
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
PremiumThe FlyCellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
25d ago
Cellectis initiated with an Overweight at Barclays
Premium
The Fly
Cellectis initiated with an Overweight at Barclays
1M ago
Cellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance Powers
Premium
Company Announcements
Cellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance Powers
1M ago
Cellectis sees cash runway into 4Q27
PremiumThe FlyCellectis sees cash runway into 4Q27
2M ago
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
Premium
Company Announcements
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
2M ago
Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
Premium
Company Announcements
Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
2M ago
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
PremiumThe FlyCellectis highlights Allogene ALPHA3 trial data, potential milestone payments
3M ago
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
Premium
Company Announcements
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
4M ago
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
Premium
Company Announcements
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100